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The method of similarity factor (f2) was recommended by the Food and Drug 156 Administration (FDA) for dissolution profile comparison 31, 32 . Two dissolution profiles were 157 considered to be similar when the value of f2 was between 50 and 100. The f2 was calculated 158 using the following equation: (1) 160 where n was the number of time points, Rt was the dissolution value of the reference profile 161 at time point t and Tt was the test profile at the same time point. The equation was applied to 162 the evaluation of differences between the formulations. Rt and Tt were replaced with the 163 dissolution value of the two formulations, respectively. 164 Design of EOP tablets 165 As described in Table 1 , different formulations were designed to study factors 166 influencing drug release profile. For example, different coating materials were used to study 167 the effect of pore-forming agent on drug release. 168 Optimization of EOP tablet 169 In order to optimize the formulation of EOP tablet, a 2-factor, 3-level face-centered 170 central composite design was applied in this study. Each factor was consisted of three groups 171 of design points: the points of the full factorial design stayed at the factor level of −1 and +1; 172 the points of the star design stayed at the levels of 0, −α and +α; and the center point stayed at 173 the factor level of 0 27, 33 . Compared with circumscribed central composite design, FCCD 174 evaluated the factors at three levels with α = 1 (Table 2) . Thus, the experimental trails were 175 composed of 9 possible combinations, including 4 factorial points, 4 axial points and 5 9 central points (Table 3) . 177 Moreover, two independent variables (factors): CA: PEG-1500 ratio (X1) and weight gain 178 (X2) were selected to study their effects on the release profile of the two drugs. The EOP 179 tablet was designed to release drugs in 12 h with zero-order release rate. Thus, four dependent 180 variables (responses): percentage of MTF released within 12 h (QMTF 12 h, Y1), R 2 of MTF 181 release data fitted to zero-order equation (RSQMTF zero, Y2), percentage of GLZ released within 182 12 h (QGLZ 12 h, Y3), and R 2 of GLZ release data fitted to zero-order equation (RSQGLZ zero, Y4) 183 were selected to evaluate the release profiles. All experiments were performed in triplicate 184 and randomized manner to eliminate a possible source of bias. 185 The statistical experimental design was performed for model qualification. The 186 regression coefficients were determined by the Design-Expert software (Version 8.0.5, 187 Stat-Ease Inc., Minneapolis, USA).
188
In vivo study in beagle dogs 189 The protocol of in vivo study was approved by the university ethics committee under the 190 guidance for care and use of laboratory animals. The in vivo study was performed in the 191 department of laboratory animal research at Shenyang Pharmaceutical University (Shenyang, 192 China). 193 A randomized, two-period crossover design was conducted to evaluate in vivo 194 performance of EOP tablet. Six healthy beagle dogs, weighing between 9 and 13 kg, were 195 used in this study. The dogs were kept overnight fasting for at least 12 h prior to experiment 196 with free access to water. All dogs were divided into two groups. One group was given two 197 conventional tablets (each tablet contains 250 mg MTF with 2.5 mg GLZ), whereas the other 198 group was given one EOP tablet (containing 500 mg MTF with 5 mg GLZ). All formulations 199 were administrated to dogs with 20 ml of water. A washout period of at least 7 days was 200 required between two consecutive administrations. 201 5 ml blood samples were obtained from cephalic vein at certain time points after 202 administration. All blood samples were kept in heparinized tubes, and immediately 203 centrifuged at 4000 rpm for 10 min. The plasma was removed and stored at −20 °C for 204 further analysis.
205

Sample preparation and analytical method 206
Determination of plasma MTF concentration: 207 0.2 ml plasma was added with 0.4 ml methanol before vortex for 1 min. The plasma was 208 centrifuged at 12,000 rpm for 10 min. 20 μL of supernatant was directly injected into the 209 column for HPLC analyses under the conditions describe below. 210 The concentration of MTF in the blood sample was analyzed by HPLC 34 (Beijing 211 Purkinje General Instrument Co.,Ltd., Beijing, China). The separation of MTF was achieved 212 on a Diamonsil C18 column (5 μm, 250 × 4.6 mm, Dikma). The mobile phase consisted of 2 213 mm sodium dodecyl sulfate solution (0.25% (v/v) triethylamine, pH 3.6) and acetonitrile 214 (64:36, v/v), and flow rate was 1.0 ml/min. The wavelength of UV detector was set at 233 nm. 215 The injection volume was 20 μl. to reach the maximum plasma concentration (Tmax) were obtained directly from the curve. 232 The area under the plasma concentration-time curve (AUC) was calculated by the trapezoidal 233 rule. AUC and Cmax were log-transformed prior to analysis with t-test. Tmax was analyzed 234 using nonparametric Wilcoxon test. Difference was considered significant with p value < 0.05. 235 The relative bioavailability of test preparation was determined by the ratio of the test 236 preparation AUC to the reference preparation AUC. The preparations were considered 237 bioequivalent if the ratio stayed within the range of 80-125%. 238 The relationship between in vitro cumulative release and the fraction of drug absorbed in 239 vivo was established with in vitro and in vivo correlation (IVIVC) and coefficient correlation 240 (R).
241
Result and Discussion
242
Design of EOP tablet and the effect of different factors in relation with release profile 243
Drug release profile of the initial formulation 244 The initial formulation is established on the basis of a previous formulation with the 245 expectation of sustained and synchronized release of MTF and GLZ (Table 1) 263 The high water-solubility of MTF comes with problem of burst release phase in a certain 264 13 formulation, resulting in difficulties in the control of drug release rate 42 . As an impermeable 265 polymer, ethyl cellulose (EC) is one of the materials with the capability to address this issue 43, 266 44 . In this study, EC is added to the formulation as both binder and release retardant. (Table 3 ). In particular, F07 is selected as the optimal formulation for the core 296 tablet. (9) 339 The above two partial derivate functions explain the variation of f in the x2 and x1 340 direction. Indeed, ∂f/∂x1 gives an exact value for every point on the slope in the x1 direction. 341 The value range of x1 in this study is 4 to 6, and that of x2 is 2.5 to 4.5. Thus, the value range Fig.3 . The overlapping 374 region shows the optimal formulation in response to every factor. The relationship between 375 experimental values and predicted ones are in agreement (Table 5 ). The cumulative release 376 profile of the optimized formulation is illustrated in Fig.4 . The f2 value of the release of MTF 377 and GLZ is 70, which indicates the two drugs release synchronously.
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378
In vivo study in beagle dogs 379 The main pharmaceutical parameters, such as Cmax, Tmax, AUC(0-24 h) and AUC(0-∞) are 380 listed in Table 6 . Fig. 5a Fig. 1 In vitro release profiles of the initial formulation of MTF and GLZ.
Fig. 2a
In vitro release profiles of MTF with different core tablets F01, F02 and F03 show the impact of NaHCO3 on MTF release, while F04, F05, F06 and F07
show the effect of release retardant on MTF release 
